Business
Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates
BURLINGTON, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the first quarter of 2025 ended on March 31, 2025. Corporate Update On March 17, 2025, we were formally notified by Nasdaq that we had regained compliance with Nasdaq Listing Rule 5550(b)(3), and as such, will continue t
About this update from Minerva Neurosciences, Inc
[{"type":"image","alt":"Minerva Neurosciences, Inc","displaySize":"","headline":null,"caption":"Minerva Neurosciences, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":266,"height":83,"url":"https://media.zenfs.com/en/globenewswire.com/f60fa0c3e62cef59eace336fa54bcafa"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MZ8bz5E62EziAC2QyixjbA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f60fa0c3e62cef59eace336fa54bcafa","width":266,"height":83}},"lazy":false},{"type":"text","content":"BURLINGTON, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the first quarter of 2025 ended on March 31, 2025. ","length":342,"tagName":"p"},{"type":"text","content":"Corporate Update","length":16,"tagName":"p"},{"type":"text","content":"On March 17, 2025, we were formally notified by Nasdaq that we had regained compliance with Nasdaq Listing Rule 5550(b)(3), and as such, will continue to be listed on the Nasdaq Capital Market.","length":193,"tagName":"p"},{"type":"text","content":"Interactions with the FDA continue with the goal of addressing questions raised in the Complete Response Letter (CRL) to our New Drug Application (NDA) for roluperidone for the treatment of negative symptoms in patients with schizophrenia as first disclosed in the first quarter of 2024.","length":287,"tagName":"p"},{"type":"text","content":"First Quarter 2025 Financial Results","length":36,"tagName":"p"},{"type":"text","content":"Research and development (R&D) expense: For the three months ended March 31, 2025 and 2024, R&D expense was $1.4 million and $4.2 million, respectively. R&D expense was lower versus the prior year period primarily due to costs associated with the FDA’s review of our NDA for roluperidone, costs for the C18 study, and lower compensation expenses.","length":358,"tagName":"p"},{"type":"text","content":"General and administrative (G&A) expense: For both the three months ended March 31, 2025 and 2024, G&A expense was $2.5 million.","length":136,"tagName":"p"},{"type":"text","content":"Non-cash interest expense: For the three months ended March 31, 2025 a...